You are here: Industry Insights > HiFiBiO

News List

HiFiBiO raises series D funds to advance immuno-oncology candidates pharmaceutical-technology
June 16, 2021
HiFiBiO Therapeutics has raised $75m in a Series D funding round, led by Mirae Asset Financial Group, to expedite its pipeline with two immuno-oncology programmes.
HiFiBiO, Pharmsynthez and IBCh sign Covid-19 antibody development deal pharmaceutical-technology
November 25, 2020
HiFiBiO Therapeutics has entered into a partnership with Pharmsynthez and Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry RAS (IBCh) to develop and commercialise its SARS-CoV-2 neutralising antibody, HFB30132A, for Covid-19 treatment.
HiFiBiO submits IND application for SARS-CoV-2 neutralising antibody to treat Covid-19 patients pharmaceutical-business-review
August 31, 2020
HiFiBiO Therapeutics announced the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for a novel SARS-CoV-2 neutralizing antibody for the treatment of Covid-19 patients.
Takeda signs antibody therapy deal with HiFiBiO pharmatimes
July 31, 2018
Takeda has signed a multi-target agreement with biotech HiFiBiO Therapeutics to enable the discovery of antibody therapies to potentially treat various gastrointestinal diseases, cancers and other disorders.
After its recent funding round, HiFiBiO pens Takeda R&D collaboration fiercebiotech
July 31, 2018
HiFiBiO Therapeutics has signed a deal with Japanese Big Pharma and biotech friend Takeda, to work on antibody therapies for various gastrointestinal diseases, cancers and other disorders.